title: Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
abstract: OBJECTIVE
  An anthracycline-based combination followed by, or combined with, a taxane is the sequence used in most adjuvant chemotherapy regimens. We hypothesized that administering the taxane before the anthracycline combination would be associated with fewer dose reductions and delays than the reverse sequence. To test this hypothesis, a randomized phase II multicenter adjuvant chemotherapy trial was performed.
  
  
  METHODS
  Fifty-six patients with axillary node-positive, nonmetastatic breast cancer were randomly assigned either to group A (docetaxel [DOC] 75 mg/m(2) intravenously [IV] every 14 days for four cycles followed by doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) [AC] IV every 14 days for four cycles); or to group B (AC followed by DOC) at the identical doses and schedule. Pegfilgrastim 6 mg subcutaneous injection was administered 1 day after the chemotherapy in all treatment cycles. The primary objective was to administer DOC without dose reductions or delays before or after AC and calculate the relative dose intensity (RDI) of DOC and AC.
  
  
  RESULTS
  The majority of toxicities were grade 0 to 2 irrespective of sequence. The RDI for DOC was 0.96 and 0.82, respectively, in groups A (DOC followed by AC) and B (AC followed by DOC), with more frequent dose reductions occurring in group B (46% v 18%). The RDI for AC was 0.95 and 0.98 in groups A and B, respectively.
  
  
  CONCLUSIONS
  The administration of DOC before AC results in fewer DOC dose reductions and a higher RDI than the reverse sequence. Larger trials evaluating the sequence of DOC before anthracyclines are justified.
authors.affiliation: Ohio State University, Columbus, OH 43210, USA.
authors.forename: Shannon
authors.initials: S
authors.lastname: Puhalla
authors.forename: Ewa
authors.initials: E
authors.lastname: Mrozek
authors.forename: Donn
authors.initials: D
authors.lastname: Young
authors.forename: Susan
authors.initials: S
authors.lastname: Ottman
authors.forename: Anne
authors.initials: A
authors.lastname: McVey
authors.forename: Kari
authors.initials: K
authors.lastname: Kendra
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Merriman
authors.forename: Mark
authors.initials: M
authors.lastname: Knapp
authors.forename: Taral
authors.initials: T
authors.lastname: Patel
authors.forename: Mark E
authors.initials: ME
authors.lastname: Thompson
authors.forename: James F
authors.initials: JF
authors.lastname: Maher
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Moore
authors.forename: Charles L
authors.initials: CL
authors.lastname: Shapiro
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001365:Axilla; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide